The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

BACKGROUND: Cetuximab is the only targeted agent approved for the treatment of head and neck squamous cell carcinomas (HNSCC), but low response rates and disease progression are frequently reported. As the phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) pathways have an...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: D'Amato, V, Rosa, R, D'Amato, C, Formisano, L, Marciano, R, Nappi, L, Raimondo, L, Di Mauro, C, Servetto, A, Fusciello, C, Veneziani, B M, De Placido, S, Bianco, R
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2014
Soggetti:
Translational Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4056056/
https://ncbi.nlm.nih.gov/pubmed/24823695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.241
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi